Successful treatment of imatinib-resistant acute megakaryoblastic leukemia with e6a2 BCR/ABL: use of dasatinib and reduced-conditioning stem-cell transplantation

Leukemia. 2007 Nov;21(11):2376-7. doi: 10.1038/sj.leu.2404792. Epub 2007 Jun 7.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adult
  • Aged
  • Benzamides
  • Dasatinib
  • Drug Resistance, Neoplasm*
  • Female
  • Fusion Proteins, bcr-abl / genetics*
  • Fusion Proteins, bcr-abl / physiology*
  • Hematopoietic Stem Cell Transplantation / methods
  • Humans
  • Imatinib Mesylate
  • Leukemia, Megakaryoblastic, Acute / drug therapy*
  • Leukemia, Megakaryoblastic, Acute / genetics*
  • Male
  • Middle Aged
  • Piperazines / pharmacology*
  • Pyrimidines / pharmacology*
  • Pyrimidines / therapeutic use
  • Recombinant Fusion Proteins / chemistry
  • Thiazoles / therapeutic use
  • Transplantation Conditioning
  • Treatment Outcome

Substances

  • Benzamides
  • Piperazines
  • Pyrimidines
  • Recombinant Fusion Proteins
  • Thiazoles
  • Imatinib Mesylate
  • Fusion Proteins, bcr-abl
  • Dasatinib